Bill
SB 1258
The bill bars insurers from requiring prior authorization for six+ months of a prescribed drug, including insulin, HIV meds, hepatis, hormones, and PrEP/PEP drugs.
Status snapshot
- Bill title: Prior Authorization — Prescription Drugs (SB 1258)
- Jurisdiction (primary text provided): Illinois — introduced Jan 28, 2025 by Sen. Graciela Guzmán (co-sponsor: Rachel Ventura). Companion: HB 2762.
- Procedural notes (from provided record): introduced 01/28/2025; public hearing noted 02/27/2025; reported joint favorable and filed with legislative counsel on 03/13/2025. (Records in the provided document also include unrelated items from other jurisdictions — see “Notes” below.)
Purpose and intent
- To limit insurers’ ability to require prior authorization (PA) for certain prescription drugs, thereby reducing administrative barriers and promoting continuity of care for patients on long‑term therapy or taking specific high‑need medications.
Key provisions
- Adds a new Section 52 to the Prior Authorization Reform Act (215 ILCS 200):
- Prohibits a health insurance issuer from requiring prior authorization for any prescription drug that has been prescribed to a patient by a health care professional for six (6) or more consecutive months, regardless of whether the drug is designated as non‑preferred under the patient’s coverage.
- Prohibits prior authorization for the following drugs or their FDA‑approved therapeutic equivalents:
- Insulin
- HIV prevention medications (PrEP)
- HIV treatment medications
- Viral hepatitis medications
- Estrogen and progesterone
- Specific named drugs: Truvada; Harvoni; Descovy; Apretude
- Also covers FDA‑approved HIV pre‑exposure prophylaxis (PrEP) and post‑exposure prophylaxis (PEP) drugs.
Who would be affected
- Patients: especially those on long‑term prescriptions (≥6 months), people with diabetes (insulin users), persons receiving HIV prevention or treatment, people treated for viral hepatitis, and those using hormone therapies.
- Prescribers and pharmacies: reduced need to submit PA requests for covered categories, potentially speeding refill/continuity processes.
- Health insurers / managed care plans: would lose PA as a utilization management tool for the enumerated situations and drugs; could affect cost and utilization oversight.
- Public health programs and payers: implementation implications for Medicaid, state employee plans, and commercial plans regulated under the Act.
Potential impact and considerations
- Benefits: improved continuity of care, fewer treatment delays, reduced administrative load on clinicians and patients.
- Tradeoffs: insurers may see increased drug spending or shift to other management strategies (formulary design, step therapy, quantity limits). The bill as drafted does not specify enforcement mechanisms, exceptions, or how to address disputed cases or changes in therapy.
- Interaction with existing law: applies to issuers covered by the Prior Authorization Reform Act; practical effect depends on regulatory implementation and whether other utilization controls remain permitted.
Procedural/timeline notes
- Introduced Jan 28, 2025. Public hearing and committee action occurred in February–March 2025 with a joint favorable report filed March 13, 2025 (per the provided record). Companion bill HB 2762 exists.
Notes on the provided document
- The packet includes a separate, unrelated Arizona statute amendment (Arizona Rev. Stat. §41‑2562) concerning state procurement and volatile organic compound (VOC) commodity specifications. That procurement language appears to be a drafting or compilation mix‑up and is not part of the Illinois prior authorization proposal summarized above.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
